Cargando…

Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients

Polycystic ovary syndrome (PCOS) is the most frequent endocrine-metabolic disorder among women at reproductive age. The diagnosis is based on the presence of at least two out of three criteria of the Rotterdam criteria (2003). In the last decades, the dysmetabolic aspect of insulin resistance and co...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrillo, Tabatha, Semprini, Elisa, Tomatis, Veronica, Arnesano, Melania, Ambrosetti, Fedora, Battipaglia, Christian, Sponzilli, Alessandra, Ricciardiello, Francesco, Genazzani, Andrea R., Genazzani, Alessandro D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406066/
https://www.ncbi.nlm.nih.gov/pubmed/36009471
http://dx.doi.org/10.3390/biomedicines10081924
_version_ 1784774032641490944
author Petrillo, Tabatha
Semprini, Elisa
Tomatis, Veronica
Arnesano, Melania
Ambrosetti, Fedora
Battipaglia, Christian
Sponzilli, Alessandra
Ricciardiello, Francesco
Genazzani, Andrea R.
Genazzani, Alessandro D.
author_facet Petrillo, Tabatha
Semprini, Elisa
Tomatis, Veronica
Arnesano, Melania
Ambrosetti, Fedora
Battipaglia, Christian
Sponzilli, Alessandra
Ricciardiello, Francesco
Genazzani, Andrea R.
Genazzani, Alessandro D.
author_sort Petrillo, Tabatha
collection PubMed
description Polycystic ovary syndrome (PCOS) is the most frequent endocrine-metabolic disorder among women at reproductive age. The diagnosis is based on the presence of at least two out of three criteria of the Rotterdam criteria (2003). In the last decades, the dysmetabolic aspect of insulin resistance and compensatory hyperinsulinemia have been taken into account as the additional key features in the etiopathology of PCOS, and they have been widely studied. Since PCOS is a complex and multifactorial syndrome with different clinical manifestations, it is difficult to find the gold standard treatment. Therefore, a great variety of integrative treatments have been reported to counteract insulin resistance. PCOS patients need a tailored therapeutic strategy, according to the patient’s BMI, the presence or absence of familiar predisposition to diabetes, and the patient’s desire to achieve pregnancy or not. The present review analyzes and discloses the main clinical insight of such complementary substances.
format Online
Article
Text
id pubmed-9406066
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94060662022-08-26 Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients Petrillo, Tabatha Semprini, Elisa Tomatis, Veronica Arnesano, Melania Ambrosetti, Fedora Battipaglia, Christian Sponzilli, Alessandra Ricciardiello, Francesco Genazzani, Andrea R. Genazzani, Alessandro D. Biomedicines Review Polycystic ovary syndrome (PCOS) is the most frequent endocrine-metabolic disorder among women at reproductive age. The diagnosis is based on the presence of at least two out of three criteria of the Rotterdam criteria (2003). In the last decades, the dysmetabolic aspect of insulin resistance and compensatory hyperinsulinemia have been taken into account as the additional key features in the etiopathology of PCOS, and they have been widely studied. Since PCOS is a complex and multifactorial syndrome with different clinical manifestations, it is difficult to find the gold standard treatment. Therefore, a great variety of integrative treatments have been reported to counteract insulin resistance. PCOS patients need a tailored therapeutic strategy, according to the patient’s BMI, the presence or absence of familiar predisposition to diabetes, and the patient’s desire to achieve pregnancy or not. The present review analyzes and discloses the main clinical insight of such complementary substances. MDPI 2022-08-09 /pmc/articles/PMC9406066/ /pubmed/36009471 http://dx.doi.org/10.3390/biomedicines10081924 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Petrillo, Tabatha
Semprini, Elisa
Tomatis, Veronica
Arnesano, Melania
Ambrosetti, Fedora
Battipaglia, Christian
Sponzilli, Alessandra
Ricciardiello, Francesco
Genazzani, Andrea R.
Genazzani, Alessandro D.
Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients
title Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients
title_full Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients
title_fullStr Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients
title_full_unstemmed Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients
title_short Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients
title_sort putative complementary compounds to counteract insulin-resistance in pcos patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406066/
https://www.ncbi.nlm.nih.gov/pubmed/36009471
http://dx.doi.org/10.3390/biomedicines10081924
work_keys_str_mv AT petrillotabatha putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients
AT semprinielisa putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients
AT tomatisveronica putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients
AT arnesanomelania putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients
AT ambrosettifedora putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients
AT battipagliachristian putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients
AT sponzillialessandra putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients
AT ricciardiellofrancesco putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients
AT genazzaniandrear putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients
AT genazzanialessandrod putativecomplementarycompoundstocounteractinsulinresistanceinpcospatients